Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
Abstract:
Targeted cancer therapies often induce "outlier" responses in molecularly defined patient subsets. One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years. Whole-genome sequencing and RNA sequencing of primary tumor and normal samples from this patient identified a somatic mutation, ARAF S214C, present in the cancer genome and expressed at high levels. Additional mutations affecting this residue of ARAF and a nearby residue in the related kinase RAF1 were demonstrated across 1% of an independent cohort of lung adenocarcinoma cases. The ARAF mutations were shown to transform immortalized human airway epithelial cells in a sorafenib-sensitive manner. These results suggest that mutant ARAF is an oncogenic driver in lung adenocarcinoma and an indicator of sorafenib response.
Insights
A rare ARAF mutation drives lung cancer and predicts response to sorafenib therapy. This finding identifies a new therapeutic target for advanced lung adenocarcinoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted cancer therapies can yield exceptional responses in specific patient groups.
- Understanding molecular drivers of outlier responses is crucial for personalized medicine.
Observation:
- A patient with advanced lung adenocarcinoma achieved long-term remission with sorafenib.
- Genomic analysis revealed a specific ARAF S214C mutation in the patient's tumor.
Findings:
- The ARAF S214C mutation was identified as a somatic mutation expressed at high levels.
- Similar ARAF mutations were found in 1% of lung adenocarcinoma cases and induced cell transformation.
- These mutant ARAF cells were sensitive to sorafenib treatment.
Implications:
- Mutant ARAF is implicated as an oncogenic driver in lung adenocarcinoma.
- ARAF mutations may serve as predictive biomarkers for sorafenib efficacy.
- This discovery opens avenues for novel targeted therapies in lung cancer.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...